SEARCH

SEARCH BY CITATION

References

  • Bain, B.J. & Catovsky, D. (1995) The leukaemic phase of non-Hodgkin's lymphoma. Journal of Clinical Pathology, 48, 189193.
  • Berinstein, N.L., Reis, M.D., Ngan, B.Y., Sawka, C.A., Jamal, H.H. & Kuzniar, B. (1993) Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. Journal of Clinical Oncology, 11, 13441352.
  • Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235242.
  • Come, S.E., Jaffe, E.S., Andersen, J.C., Mann, R.B., Johnson, B.L., DeVita, V.T.Jr. & Young, R.C. (1980) Non-Hodgkin's lymphomas in leukemic phase: clinicopathologic correlations. American Journal of Medicine, 69, 667674.
  • Criel, A., Pittaluga, S., Verhoef, G., Wlodarska, I., Meeus, P., Mecucci, C., Van Orshoven, A., Van den Berghe, H., Boogaerts, M. & De Wolf-Peeters, C. (1996) Small B cell NHL and their leukemic counterpart: differences in subtyping and assessment of leukemic spread. Leukemia, 10, 848853.
  • De Paepe, P. & De Wolf-Peeters, C. (2007) Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia, 21, 3743.
  • Drillenburg, P. & Pals, S.T. (2000) Cell adhesion receptors in lymphoma dissemination. Blood, 95, 19001910.
  • Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 41174126.
  • Flowers, C.R., Sinha, R. & Vose, J.M. (2010) Improving outcomes for patients with diffuse large B-cell lymphoma. CA: A Cancer Journal for Clinicians, 60, 393408.
  • Gascoyne, R.D., Rosenwald, A., Poppema, S. & Lenz, G. (2010) Prognostic biomarkers in malignant lymphomas. Leukaemia & Lymphoma, 51 (Suppl 1), 1119.
  • Hong, J., Park, S., Park, J., Kim, H.S., Kim, K.H., Ahn, J.Y., Rim, M.Y., Jung, M., Sym, S.J., Cho, E.K., Shin, D.B. & Lee, J.H. (2011) Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leukaemia & Lymphoma, 52, 19041912.
  • Jaffe, E.S. (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology/The Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ??????, 523531.
  • Kaplan, E.L. & Meier, P. (1958) Nonparametric-estimation from incomplete observations. Journal of the American Statistical Association, 53, 457481.
  • Maruyama, D., Watanabe, T., Maeshima, A.M., Nomoto, J., Taniguchi, H., Azuma, T., Mori, M., Munakata, W., Kim, S.W., Kobayashi, Y., Matsuno, Y. & Tobinai, K. (2010) Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. International Journal of Hematology, 92, 732743.
  • Matos, D.M., Rizzatti, E.G., Garcia, A.B., Gallo, D.A. & Falcao, R.P. (2006) Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase. Brazilian Journal of Medical and Biological Research, 39, 13491355.
  • Mintzer, D.M. & Hauptman, S.P. (1983) Lymphosarcoma cell leukemia and other non-Hodgkin's lymphomas in leukemic phase. American Journal of Medicine, 75, 110120.
  • Morra, E., Lazzarino, M., Orlandi, E., Pagnucco, G., Brusamolino, E., Castello, A., Inverardi, D. & Bernasconi, C. (1984) Leukemic phase of non-Hodgkin's lymphomas. Hematological features and prognostic significance. Haematologica, 69, 1529.
  • Morra, E., Lazzarino, M., Castello, A., Inverardi, D., Coci, A., Pagnucco, G., Orlandi, E., Merante, S., Magrini, U., Zei, G. & Bernasconi, C. (1989) Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation. European Journal of Haematology, 42, 445453.
  • Muringampurath-John, D., Flowers, C.R., Toscano, M., Zhengjia, C., Kaufman, J.L., Arellano, M., Bernal-Mizrachi, L., Heffner, L.T., Lechowicz, M.J., McLemore, M., Winton, E., Jaye, D.L., Lonial, S. & Khoury, H.J. (2012) Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leukaemia & Lymphoma, 53, 725727.
  • Nogai, H., Dorken, B. & Lenz, G. (2011) Pathogenesis of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 29, 18031811.
  • Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. & Staudt, L.M. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 19371947.
  • Schwartz, D.L., Pierre, R.V., Scheerer, P.P., Reed, E.C.Jr. & Linman, J.W. (1965) Lymphosarcoma cell leukemia. American Journal of Medicine, 38, 778786.
  • Shenoy, P.J., Malik, N., Nooka, A., Sinha, R., Ward, K.C., Brawley, O.W., Lipscomb, J. & Flowers, C.R. (2011) Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer, 117, 25302540.
  • Shipp, M.A., Ross, K.N., Tamayo, P., Weng, A.P., Kutok, J.L., Aguiar, R.C., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G.S., Ray, T.S., Koval, M.A., Last, K.W., Norton, A., Lister, T.A., Mesirov, J., Neuberg, D.S., Lander, E.S., Aster, J.C. & Golub, T.R. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine, 8, 6874.
  • Sieniawski, M., Bhartia, S., Wilkinson, J. & Proctor, S.J. (2009) Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone–rituximab refractory patients. Leukaemia & Lymphoma, 50, 17261730.
  • The Non-Hodgkin's Lymphoma Classification Project(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood, 89, 39093918.
  • Villamor, N., Rozman, M., Esteve, J., Aymerich, M., Colomer, D., Aguilar, J.L., Campo, E. & Montserrat, E. (1999) Anaplastic large-cell lymphoma with rapid evolution to leukemic phase. Annals of Hematology, 78, 478482.